Publicaciones en colaboración con investigadores/as de Hospital Italiano de Buenos Aires (13)

2022

  1. Guidelines on the management of mineral and bone metabolism disorders during pregnancy and lactation

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 7, pp. 530-539

2020

  1. Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 3, pp. 205-215

2018

  1. Consensus document on osteoporosis in males

    Endocrinologia, Diabetes y Nutricion, Vol. 65, pp. 9-16

2017

  1. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

  2. Recommendations on the effect of antidiabetic drugs in bone

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 1-6

  3. Recommended vitamin D levels in the general population

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 7-14

  4. Transancestral mapping and genetic load in systemic lupus erythematosus

    Nature Communications, Vol. 8

2015

  1. Multiplex Real-Time PCR Assay Using TaqMan Probes for the Identification of Trypanosoma cruzi DTUs in Biological and Clinical Samples

    PLoS Neglected Tropical Diseases, Vol. 9, Núm. 5

2013

  1. Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression

    PLoS Genetics, Vol. 9, Núm. 10

2009

  1. Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus

    Human Molecular Genetics, Vol. 18, Núm. 19, pp. 3739-3748

  2. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans

    Journal of Clinical Investigation, Vol. 119, Núm. 4, pp. 911-923

2007

  1. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 56, Núm. 4, pp. 1234-1241

1999

  1. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

    Osteoporosis International, Vol. 9, Núm. 5, pp. 461-468